Advanced or metastatic NSCLC sufferers with EGFR mutations, providing far more choices
Sophisticated or metastatic NSCLC patients with EGFR mutations, supplying far more options for these patients. Dacomitinib also shows superiority in OS, specifically in the subgroup with exon 21 L858R substitution…